Taken together, we hypothesize that ACAT1 inhibition by avasimibe suppresses the proliferation and metastasis of BLCA cells, and that this effect may be related to disturbed cholesterol metabolism. Here, ACAT1 is linked to bladder transitional cell carcinoma.